S1111 Non-Alcoholic Fatty Liver Disease Is Associated With Increased Disease Severity in Patients With COVID-19

Steiner, Claudia; Berinstein, Jeffrey; Hsu, Chi-Yang; Louissaint, Jeremy; Platt, Kevin D.; Reddy, Chankyaram A.; Kassab, Ihab; Hawa, Fadi; Gunaratnam, Naresh T.; Sharma, Pratima; Chen, Vincent

doi:10.14309/01.ajg.0000706492.51966.80

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The included studies were from 5 countries. Two studies were from China, 15,16 2 from the United States, 17,18 and 1 each from Qatar, 10 the United Kingdom, 9 and Israel. 19 One study was a case-control study, 1 was a cohort study, and the remaining 5 were cross-sectional studies.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Risk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease

Tao

Cheng

et al. 2021

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Background: The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) in coronavirus disease-2019 (COVID-19) patients and whether it affects the outcomes of COVID-19 requires investigation. Goals: The aim was to determine the prevalence of MAFLD among COVID-19 patients and its influence on the outcomes of COVID-19 by meta-analysis. Methods: Our study protocol has been registered on PROSPERO (CRD42021242243). The studies published on PubMed, Embase, Cochrane Library, and Web of Science before March 11, 2021 were screened. The Newcastle-Ottawa scale (NOS) and Agency for Healthcare Research and Quality scale were used to assess the quality of the studies. Pooled analysis was conducted using the software RevMan version 5.3 and Stata version 15.0 SE. The stability of the results was assessed by sensitivity analysis. Publication bias was evaluated using funnel plots, Egger test, and trim-and-fill analysis. Results: Seven studies covering 2141 COVID-19 patients were included. It was confirmed that MAFLD increased the risk of severe COVID-19 (odds ratios: 1.80, 95% confidence interval: 1.53-2.13, P<0.00001). No association was found between the presence of MAFLD and the occurrence of COVID-19 death. The pooled prevalence of MAFLD among COVID-19 patients was 36% (95% confidence interval: 0.23-0.49, P<0.00001). Sensitivity analysis confirmed that the initial results were stable. Conclusions: MAFLD can increase the incidence of severe COVID-19, but the correlation between MAFLD and COVID-19 death has not been confirmed. Further investigation is needed to explore the possible mechanism of this association. Since MAFLD is common among patients infected with SARS-CoV-2, more care should be given to COVID-19 patients with underlying MAFLD.

show abstract

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Risk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease

Tao

Cheng

et al. 2021

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Meanwhile, imaging techniques such as ultrasound or computed tomography (CT) are the primary tools used to identify the presence of fatty liver [ 57 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 ]. The use of a liver biopsy to confirm NAFLD is a rare occurrence in the literature [ 74 ].…”

Section: The Role Of Mafld In the Progression Of Covid-19mentioning

confidence: 99%

“…It should be noted that the use of blood-based surrogate scores or imaging techniques (ultrasound, CT) during hospitalization for COVID-19 to diagnose NAFLD does not provide information about the presence of fatty liver before the emergence of COVID-19. Control groups often have fewer patients with classic metabolic factors, such as diabetes mellitus and obesity, compared to the corresponding NAFLD groups [ 57 , 75 , 78 ]. As a result, this metabolic imbalance among study groups cannot be easily addressed through multivariate analysis.…”

Section: The Role Of Mafld In the Progression Of Covid-19mentioning

confidence: 99%

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

Buchynskyi

Kamyshna

Oksenych

et al. 2023

Viruses

View full text Add to dashboard Cite

The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. With our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardiovascular apparatus, the multiorgan symptoms of this infectious disease have been discerned. Metabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a pervasive public health concern intricately linked with metabolic dysregulation and estimated to afflict one-fourth of the global adult population. The burgeoning focus on the association between COVID-19 and MAFLD is justified by the potential role of the latter as a risk factor for both SARS-CoV-2 infection and the subsequent emergence of severe COVID-19 symptoms. Investigations have suggested that changes in both innate and adaptive immune responses among MAFLD patients may play a role in determining the severity of COVID-19. The remarkable similarities observed in the cytokine pathways implicated in both diseases imply the existence of shared mechanisms governing the chronic inflammatory responses characterizing these conditions. The effect of MAFLD on the severity of COVID-19 illness remains uncertain, as indicated by conflicting results in cohort investigations.

show abstract

“…Meanwhile, imaging techniques such as ultrasound or computed tomography (CT) are the primary tools used to identify the presence of fatty liver [48,57,[66][67][68][69][70][71][58][59][60][61][62][63][64][65]. The use of liver biopsy to confirm NAFLD is a rare occurrence in the literature [61].…”

Section: The Role Of Mafld In the Progression Of Covid-19mentioning

confidence: 99%

“…It should be noted that the use of blood-based surrogate scores or imaging techniques (ultrasound, CT) during hospitalization for COVID-19 to diagnose NAFLD does not provide information about the presence of fatty liver before the emergence of COVID-19. Control groups often have fewer patients with classic metabolic factors, such as diabetes mellitus and obesity, compared to the corresponding NAFLD groups [48,62,65]. As a result, this metabolic imbalance of study groups cannot be easily addressed through multivariate analysis.…”

Section: The Role Of Mafld In the Progression Of Covid-19mentioning

confidence: 99%

The Intersection of COVID-19 and MAFLD: An Overview of the Current Evidence

Buchynskyi¹,

Kamyshna²,

Oksenych³

et al. 2023

Preprint

View full text Add to dashboard Cite

The global population is currently experiencing the impact of the SARS-CoV-2 coronavirus, which has caused the Coronavirus Disease 2019 (COVID-19) pandemic. By our profound comprehension of COVID-19, encompassing the involvement sequence of the respiratory tract, gastrointestinal system, and cardiovascular apparatus, the multiorgan symptoms of this infectious disease have been discerned. Metabolic-associated fatty liver disease (MAFLD) is a pervasive public health concern, intricately linked with metabolic dysregulation and estimated to afflict one-fourth of the global adult population. The burgeoning focus on the association between COVID-19 and metabolic dysfunction-associated fatty liver disease (MAFLD) is justified by the potential role of the latter as a risk factor for both SARS-CoV-2 infection and the subsequent emergence of severe COVID-19 symptoms. Investigations have suggested that changes in both innate and adaptive immune responses among metabolic dysfunction-associated fatty liver disease (MAFLD) patients may play a role in determining the severity of COVID-19. The remarkable similarities observed in the cytokine pathways implicated in both diseases imply the existence of shared mechanisms governing the chronic inflammatory responses characterizing these conditions. The effect of metabolic dysfunction-associated fatty liver disease (MAFLD) on the severity of COVID-19 illness remains uncertain, as indicated by conflicting results in cohort investigations.

show abstract

S1111 Non-Alcoholic Fatty Liver Disease Is Associated With Increased Disease Severity in Patients With COVID-19

Cited by 3 publications

References 0 publications

Risk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease

Risk of Severe COVID-19 Increased by Metabolic Dysfunction-associated Fatty Liver Disease

The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence

The Intersection of COVID-19 and MAFLD: An Overview of the Current Evidence

Contact Info

Product

Resources

About